Jci_page_head_homepage_01 Jci_page_head_homepage_02
Dai Miyazaki, Takao Nakamura, Masako Toda, Kam-Wa Cheung-Chau, Ricardo M. Richardson, Santa Jeremy Ono
Published in Volume 115, Issue 2
J Clin Invest. 2005; 115(2):434–442 doi:10.1172/JCI18452
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 7

Augmentation of allergen-induced histamine release by MIP-1α. The experimental design involved a passive sensitization assay using isolated conjunctival tissue from naive mice. The upper panel shows histamine release from the in vitro–sensitized tissue challenged with eotaxin-1 (100 ng/ml), MIP-1α (100 ng/ml), or compound 48/80 (1 mg/ml) without HSA-DNP (allergen) addition. The lower panel shows histamine release from the in vitro–sensitized tissue challenged with HSA-DNP in media, eotaxin-1 (100 ng/ml), or MIP-1α (100 ng/ml). MIP-1α supplementation significantly augmented allergen–induced (HSA-DNP–induced) histamine release of in vitro–sensitized conjunctival mast cells, while eotaxin-1 or vehicle had no effect. Compound 48/80 solution served as a positive control of mast cell degranulation. Values are expressed as mean ± SEM.